GE Healthcare announced recently that the FDA has approved the first imaging agent to help physicians in evaluating neurodegenerative movement disorders.
GE Healthcare announced recently that the FDA has approved the first imaging agent to help physicians in evaluating neurodegenerative movement disorders.
The FDA approved ioflupane I 123 injection (DaTscan), a radiopharmaceutical agent intended for use with single photon emission computed tomography (SPECT) imaging, for the detection of dopamine transporters in the brains of adult patients with suspected parkinsonian syndromes.
Along with other evaluations, DaTscan may be used to differentiate essential tremor from tremors due to these syndromes, the company said.
“It is important for me to provide a patient as confident as diagnosis as possible,” said Mark Stacy, MD, neurologist and director of the Duke Movement Disorders Clinic at Duke University Medical Center in Durham, NC, and a consultant to GE Healthcare in the development of DaTscan. “In cases where there is not a clear constellation of clinical signs pointing to Parkinson's disease or essential tremor, DaTscan may help me counsel a patient with more confidence. I think this is helpful to the patient in the long run.”
The DaTscan could supplant some evaluations, Stacy said in an interview, such as an MRI or CT scan. In some cases, it may make more sense to use the DaTscan, he said.
FDA’s move, after priority review, is the first approval of a radiopharmaceutical agent to detect DaT distribution in the brain, according to the company. The FDA grated priority review “due to an unmet clinical need for an imaging agent to assist physicians in managing patients according to their dopaminergic status,” the company said.
Stacy said that movement disorders are now diagnosed through clinical exams, blood tests, and neuropsychological evaluations, which are not conclusive. “A new diagnostic adjunct to existing clinical assessments represents a meaningful contribution to the movement disorders field,” he said in the statement.
According to Medscape Medical News, a few members of the FDA advisory panel expressed some concerns about the product last fall. Members who voted against the agent questioned its safety, and one member voiced concern that it wasn’t cost-effective.
Stacy noted that the FDA reviewed the data and approved the agent, and that the DaTscan has been used in Europe since 2000.
AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses on CT
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Clears AI-Powered Qualitative Perfusion Mapping for Cone-Beam CT
May 6th 2024Reportedly validated in more than 10 clinical trials, the AngioFlow perfusion imaging software enables timely identification of brain regions with cerebral blood flow reduction and those with significant hypoperfusion.
Can a CT-Based Radiomics Model Bolster Detection of Malignant Thyroid Nodules?
May 3rd 2024A computed tomography (CT)-based radiomics model that includes 28 radiomic features showed significantly higher accuracy, sensitivity, and specificity than conventional CT in differentiating benign and malignant thyroid nodules, according to newly published research.